BioNTech Announces Appointment of Guido Oelkers to Management Board as Chief Executive Officer

Summary by AI BETAClose X

BioNTech SE announced the appointment of Guido Oelkers as Chief Executive Officer, effective by February 1, 2027, succeeding Prof. Ugur Sahin. Oelkers joins from Swedish Orphan Biovitrum AB, where he served as CEO since 2017 and quadrupled revenues between 2017 and 2026, significantly increasing profitability and strengthening the late-stage pipeline. BioNTech's Supervisory Board highlighted Oelkers' experience in scaling innovation-driven organizations and his deep market knowledge as crucial for the company's evolution into a multi-product entity. Oelkers expressed his commitment to advancing BioNTech's oncology pipeline and its strategy to become a global biopharmaceutical company with multiple approved products by 2030, aiming to create sustainable long-term value.

Disclaimer*

UK 100

Latest directors dealings